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Abstract
 .A system for expression and facile purification of the human P-glycoprotein Pgp from the yeast Saccharomyces
cere˝isiae is described. The wild-type human mdr1 cDNA was cloned into a high copy number yeast expression vector
under the control of the constitutive promoter of the yeast plasma membrane Hq-ATPase. Western blots of membranes from
the stable transformants confirmed that the Pgp is expressed in yeast cells in amounts approximately 0.4% of the total yeast
membrane protein. Density gradient sedimentation analysis of the yeast membranes indicated that the expressed Pgp is
localized in the plasma membrane. Yeast cells transformed with the Pgp expression plasmid acquire increased resistance to
valinomycin, suggesting that the expressed Pgp is properly folded and functional. The expressed Pgp can be solubilized
from the yeast membranes with lysophosphatidylcholine, and when tagged with ten histidines at its C-terminus, can be
readily purified to about 90% homogeneity by Ni2q affinity chromatography. About 50 mg of the Pgp can be purified from
20 mg of crude yeast membranes. The purified human Pgp exhibits a verapamil-stimulated ATPase activity and the
maximal activity is 2.5"0.5 mmolrmin per mg of Pgp, suggesting that the purified Pgp from yeast is highly functional.
 .The Pgp expressed in yeast has the same electrophoretic mobility ca. 130 kDa as the Pgp produced in Sf9 insect cells and
is unaffected by N-glycosidase treatment, suggesting that it is not glycosylated. Because of the relative ease of growing
yeast in massive quantities this expression system appears to be excellent for producing this membrane transporter at levels
sufficient for further biochemical and biophysical studies, and for site-directed mutagenesis studies as well. q 1997 Elsevier
Science B.V.
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1. Introduction
 .The development of multidrug resistance MDR
in cancer is a significant obstacle to the successful
chemotherapy of cancer. A major form of MDR is
caused by the over-expression of a 170 kDa mem-
 .brane protein known as the P-glycoprotein Pgp . The
Pgp is generally thought to pump a variety of struc-
turally and functionally unrelated hydrophobic antitu-
mor agents out of resistant tumor cells, thus sparing
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w xthem from the killing action of these drugs 1–4 ,
although alternative explanations of the available data
w xhave been proposed 5 . Human Pgp is encoded by
the mdr1 gene, and shares significant sequence ho-
w xmology with several bacterial transporters 6 and
with mammalian proteins such as the cystic fibrosis
 .transmembrane conductance regulator CFTR . It be-
 .longs to the ATP-binding cassette ABC or traffic-
w xATPase superfamily of transport proteins 7,8 . Al-
though extensive biochemical studies have been car-
ried out with the Pgp, much remains to be learned
about its structure and molecular mechanism of drug
transport. Future efforts to understand in more detail
the structure and function of the Pgp will require
large quantities of purified functional protein. Since
the endogenous levels of the human Pgp in natural
sources are low, suitable starting materials for Pgp
purification can only be obtained from overproducing
cultured cell lines or high-yield heterologous expres-
sion systems. Excellent Pgp production and purifica-
tion systems using cultured drug-resistant cell lines
w xhave been recently reported 9–12 . However, major
drawbacks of these systems are the expense and labor
inherent in tissue culture systems and the inability to
mutate the Pgp. Heterologous expression systems for
w x w xthe Pgp in yeast 13–15 , Sf9 insect cells 16,17 , E.
w xcoli 18,19 , and transiently transfected human em-
 . w xbryonic kidney 293 HEK293 cells 20 have been
developed in recent years. The Sf9 insect cellrbacu-
lovirus expression system appears to be a promising
system for providing large amounts of starting mate-
rial for biochemical studies but it involves cell cul-
ture techniques as difficult and expensive as the
drug-resistant animal cell systems. Recently, human
Pgp and its mutants have been purified from tran-
siently transfected HEK293 cells but yields of puri-
w xfied protein are relatively low 20 . In contrast to
cultured cell systems, yeast expression systems re-
quire only simple culture techniques and inexpensive
media and allow the production of substantial quanti-
ties of eukaryotic proteins. Moreover, the thoroughly
developed methodology and the readily manipulated
techniques of yeast molecular genetics can provide
novel approaches for studying the expressed proteins,
which is more difficult in mammalian and insect cell
expression systems. Although the mouse and the
w xhuman Pgps have been expressed in yeast 13–15 ,
the expression levels are difficult to estimate from the
data presented. In this laboratory, yeast expression
systems for the Neurospora crassa plasma mem-
q w x w xbrane H -ATPase 21 and the CFTR 22 have re-
cently been developed, based on the system estab-
w xlished by Serrano and co-workers 23 . The success
of these studies prompted us to extend this expression
system to the human Pgp. In the present study we
report a yeast expression system that produces func-
tional human Pgp in reasonable yield and allows for
subsequent facile solubilization and purification of
the Pgp to near homogeneity. The availability of this
new expression system may facilitate future studies
for elucidating the structure and molecular mecha-
nism of this clinically important membrane transport
protein.
2. Materials and methods
2.1. Plasmid constructions
w xStandard recombinant DNA techniques 24 were
used to construct plasmids containing the human
mdr1 cDNA for expression in Saccharomyces cere-
˝isiae. We began with the expression vector
pSKMHA9, which was previously used for expres-
sion of the Neurospora crassa plasma membrane
q w xH -ATPase in yeast 25 . To remove the majority of
the Hq-ATPase cDNA from the expression vector,
pSKMHA9 was digested with NcoI and NdeI, treated
with Klenow enzyme, and religated. The resulting
plasmid was digested with XhoI and religated to
produce plasmid pSKMHA9NyNyXy. The wild-type
human mdr1 cDNA, taken from plasmid pHaM-
w xDRGA 26 by digestion with BstUI and XhoI, was
then ligated with the vector fragment produced from
pSKMHA9NyNyXy by digestion with Not I, filling
in the ends with Klenow enzyme, and digestion with
XhoI. This construct, pMDR1, contains the coding
region of the wild-type human Pgp in a yeast expres-
sion vector under the control of the constitutive pro-
moter of the yeast plasma membrane Hq-ATPase.
Pst I, SalI and SphI sites in the polylinker of
pMDR1 were then deleted by digestion of pMDR1
with BamHI and SphI, filling in the ends with
Klenow enzyme, and religation to produce plasmid
pQMMDR1 in which there is an unique PstI site
about 500 base pairs upstream from the stop codon of
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the mdr1 cDNA. To facilitate Pgp purification, a
histidine tag containing 10 tandem histidines was
introduced at the C-terminus as follows: Two primers
were designed to amplify a PCR product containing
the histidine tag using pQMMDR1 as template. One
primer annealed between Bcl I and PstI sites, and the
other annealed to the 3X end of the mdr1 cDNA. The
latter primer contained a DNA sequence coding for a
histidine tag which was immediately followed by a
TAG stop codon, and MluI and XhoI sites. The PCR
fragment containing a histidine tag was then digested
with Pst I and XhoI, and cloned into pQMMDR1
digested with the same enzymes. The resulting con-
struct was named pQMMDR2.
Because of the observation that translation initia-
tion may occur at an in-frame ATT upstream from
w xthe ATG start codon 22 , which may cause N-termi-
nal extension of the translated protein, the sequence
containing all of three such ATTs present in pQM-
MDR2 were deleted by overlap extension using the
w xpolymerase chain reaction 27 and, at the same time,
an unique SacII site was introduced immediately
preceding the ATG start codon, as shown in Fig. 1.
To do this, a PCR fragment of approximately 2.3 kb
was produced by overlap extension of two PCR
products obtained from the first PCRs from SmaI and
 .ApaI to mutagenic primers see Fig. 1 , and then the
Fig. 1. Plasmid map of pQMMDR4. Plasmid pQMMDR4 en-
codes the human Pgp under the control of the constitutive
promoter of the yeast plasma membrane Hq-ATPase. Codons for
a histidine tag at the C-terminus of the Pgp are also included. The
filled box represents the cDNA of the Pgp, and the arrow of the
filled box indicates the sense direction of the cDNA. Some
important restriction sites used for cloning are indicated as well
as several important genetic markers.
2.3 kb PCR product, in which the sequence upstream
from the ATG start codon is exactly the same as that
in the expression plasmid pHCFTRW as described by
w xHuang et al. 22 , was digested with SmaI and ApaI,
purified in low-melting agarose and ligated with the
vector fragment from pQMMDR2 also digested with
SmaI and ApaI. This construct, pQMMDR4, is shown
in Fig. 1. It contains codons for a histidine tag
attached to the C-terminus of the Pgp and has deleted
all of three in-frame ATTs upstream from the ATG
start codon. The same PCR fragment was also cloned
into pMDR1 to produce plasmid pQMMDR3. Fi-
nally, both DNA sequences within the mdr1 cDNA
 .from SacII to ApaI, and from Pst I to XhoI gener-
ated by PCR were completely sequenced at the UNC-
CH Automated DNA Sequencing Facility on a Model
 .373A DNA Sequencer Applied Biosystems using
the Taq DyeDeoxye Terminator Cycle Sequencing
 .Kit Applied Biosystems before yeast transformation
to confirm that no errors had been introduced.
2.2. Strain and media
S. cere˝isiae proteinase-deficient strain BJ1991
 .a leu2 trp1 ura3-52 prb1-1122 pep4-3 gal2 was
used for transformation with the leu2 plasmids
throughout this work. Yeast clones transformed with
leu2 plasmids were grown on synthetic medium con-
 .taining 0.17% wrv yeast nitrogen base without
 .amino acids, 0.5% wrv ammonium sulfate, 2%
 .  .wrv D-glucose, 0.2 mM adenine, and 0.2% wrv
of an amino acid mixture lacking leucine SC-LEU,
.Bio101, La Jolla, CA . Untransformed yeast cultures
were grown in the same medium but supplemented
with 1 mM L-leucine. Solid media additionally con-
 .tained 1.5% wrv Difco agar and, in certain cases,
 .150 mM valinomycin Sigma added from ethanol
solution.
2.3. Yeast transformation and growth tests
Transformation of yeast cells was carried out as
w xdescribed previously 21 . Transformation of yeast
strain BJ1991 with plasmids pQMMDR3 and pQM-
MDR4 gave rise to yeast strains QMMDR3 and
QMMDR4. Transformation with the control plasmid
w xpRS421-Not 21 , which does not contain the mdr1
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cDNA, gave rise to strain RS421-Not. For growth
rate experiments, cells were first grown in synthetic
medium to an A of about 1. Subsequently, for600nm
the liquid growth assay, cells were diluted in the
same medium to A s0.015. The diluted cells600nm
 .were then grown with constant agitation 140 rpm at
308C, and growth was monitored by measuring the
A . For the quantitative analysis of valinomycin600nm
resistance of Pgp-expressing yeast cells, cells were
diluted to A (0.05, the diluted cells were grown600nm
 .with constant agitation 140 rpm at 308C, and cell
growth was scored every 2–4 h as the A . Vali-600nm
nomycin was added into the media from ethanol
solution. Growth on solid media was assessed using a
w xdrop test, similar to that previously described 21 .
Briefly, the Pgp and control transformants grown to
A (1 were diluted to the same cell concentra-600nm
tions, and then 104 cells were spotted on agar plates
with or without valinomycin. Cell growth was
recorded after 48 h at 308C.
2.4. Isolation of membranes
As for the expression of the AE1 anion exchanger
w xin yeast 28 , we have observed that the slowest
growing transformants express the highest level of
the Pgp. Therefore, only the slowest growing trans-
formants, which usually have a doubling time greater
than 7 h, were selected for membrane preparation.
Cells of strain QMMDR4 grown to A (1 were600nm
harvested by centrifugation, washed with cold water
and resuspended in homogenization buffer, as de-
w xscribed previously 21,22 with minor modifications.
The homogenization buffer contained 25 mM Tris, 1
mM EDTA, 1 mM PMSF, 2 mgrml chymostatin,
leupeptin, pepstatin A and aprotinin, 1 mM b-mer-
 .captoethanol, and 10% wrv glycerol, pH 7.5 with
HCl. Then 5–10 g of yeast cells in 20 ml of homoge-
nization buffer were mixed with 50 g of glass beads
and cooled to y58C for 10 min in a freezer and the
cells were then broken in a Braun cell homogenizer
 .B. Braun Biotech Inc., Allentown, PA for 45 sec.
The homogenizer chamber was kept at 48C using
liquid CO during the homogenization process. Cell2
debris and glass beads were separated from the super-
natant fluid and washed once with 10 ml of homoge-
nization bufferrg of cells by centrifugation for 10
 .min at 1600=g 48C . Both supernatant fluids were
pooled and the membranes were sedimented by cen-
trifugation for 1 h at 200 000=g at 48C. The mem-
branes were resuspended in storage buffer containing
25 mM Tris, 1 mM EDTA, 1 mM PMSF, 2 mgrml
chymostatin, leupeptin, pepstatin A and aprotinin, 1
 .mM b-mercaptoethanol, and 20% wrv glycerol,
pH 7.5 with HCl. The protein concentration of the
membrane suspensions was 11–13 mgrml. The
membrane suspensions were divided into aliquots and
stored at y808C until use.
2.5. Sucrose gradient centrifugation
The isolated membranes in storage buffer 3 mg of
.protein were layered on the top of a discontinuous
sucrose gradient containing 2 ml aliquots of 25%,
 .30%, 35%, 40% and 45% wrv sucrose in gradient
buffer in a 12 ml centrifuge tube. The gradient buffer
contained 10 mM Tris, 1 mM EDTA, 1 mM PMSF, 2
mgrml chymostatin, leupeptin, pepstatin A and apro-
tinin, and 1 mM b-mercaptoethanol, pH 7.5 with
HCl. The gradient was centrifuged at 150 000=g for
3 h at 48C in a Beckman SW 40 Ti rotor. Fractions
 .0.7 ml each were collected from the top of the
gradient and assayed for protein concentration. Then
20 mg of protein from membrane-containing frac-
tions from the top to the bottom of the gradient was
treated and analyzed essentially as described previ-
w xously 22 . The Pgp was first detected using immuno-
blotting. After a luminogram of immunostaining for
the Pgp had been obtained the same blot was washed
w xfor 1 h in TBS–Tween buffer 17 and reblotted for
the yeast plasma membrane Hq-ATPase.
2.6. Solubilization and purification of the expressed
recombinant human Pgp
 .Typically, membranes 20 mg of protein were
washed twice with buffer A 25 mM Tris, 1 mM
PMSF, 400 mM NaCl, 2 mgrml chymostatin, leu-
peptin, pepstatin A and aprotinin, 1 mM b-mercapto-
 .ethanol, 20 mM imidazole, and 20% wrv glycerol,
. pH 8.0 with HCl by centrifugation 100 000=g, 15
. min, 48C and were then solubilized with LPC Sigma,
.from egg yolk, approximately 99% pure at a ratio of
5 mg LPCrmg membrane protein in buffer A at a
protein concentration of 2 mgrml. After incubation
( )Q. Mao, G.A. ScarboroughrBiochimica et Biophysica Acta 1327 1997 107–118 111
with gentle stirring for 20 min at 48C, the solution
 .was centrifuged 100 000=g, 45 min, 48C to re-
move insoluble materials. The supernatant fluid con-
taining the solubilized Pgp was then mixed with 1 ml
2q of Ni -NTA resin equilibrated with buffer B 25
mM Tris, 1 mM PMSF, 400 mM NaCl, 2 mgrml
chymostatin, leupeptin, pepstatin A and aprotinin, 1
mM b-mercaptoethanol, 30 mM imidazole, 20%
 .  . wrv glycerol, and 0.1% wrv DDM Boehringer
. .Mannheim, Mannheim, Germany , pH 8.0 with HCl
and gently shaken for 1 h at 48C. The resin with the
adsorbed protein was then packed into a 1=5 cm
 .column Bio-Rad . After the flow-through was passed
and collected, the column was washed with 10 ml of
buffer B and 20 ml of buffer C 25 mM Tris, 1 mM
PMSF, 400 mM NaCl, 2 mgrml chymostatin, leu-
peptin, pepstatin A and aprotinin, 1 mM b-mercapto-
 .ethanol, 60 mM imidazole, 20% wrv glycerol, and
 . .0.1% wrv DDM, pH 7.5 with HCl . The Pgp was
then eluted with buffer D 25 mM Tris, 1 mM PMSF,
20 mM NaCl, 2 mgrml chymostatin, leupeptin, pep-
statin A and aprotinin, 1 mM b-mercaptoethanol, 250
 .  .mM imidazole, 20% wrv glycerol, and 0.1% wrv
.DDM, pH 7.5 with HCl . The flow rate was set to 0.5
mlrmin and 1 ml fractions were collected. Fractions
 .were analyzed by SDS–PAGE in 7.5% wrv acryl-
amide gels, which were either stained with alkaline
w xsilver 29 or transferred to nitrocellulose membranes
for immunostaining of the Pgp. The fractions contain-
ing the Pgp were pooled and assayed for protein
concentration. Purified Pgp samples were concen-
 .trated to 0.3 mgrml in a Centricon 100 Amicon
and stored in aliquots at y208C until use. Solubiliza-
tion and purification of the Pgp were carried out at
48C.
2.7. Pgp ATPase acti˝ity assay
 .Purified Pgp 150 ng was incubated at 378C in 0.1
ml of buffer containing 50 mM Tris, pH 7.4 with
HCl, 4 mgrml acetonerether-precipitated E. coli
 .lipids Avanti Polar Lipids, Alabaster, AL , 5 mM
MgSO , and 5 mM NaATP for 20 min. Verapamil4
 .Sigma was included in the assay mixtures at a
variety of concentrations. Reactions were stopped by
 .the addition of 0.1 ml of 5% wrv SDS and the
amount of inorganic phosphate released was deter-
mined immediately, as described by Sarkadi et al.
w x17 . The added verapamil solution made no contribu-
tion to the color reaction in control incubations.
2.8. Sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis, staining and immunoblotting
SDS–PAGE and immunoblotting were carried out
w xessentially as described 17,21,22 . Electrophoresis
 .was usually carried out in 7.5% wrv SDS–PAGE
minigels in a Bio-Rad Mini-Protean II electrophoresis
cell. In some cases, electrophoresis was carried out in
15=15=0.075 cm gels in a Hoefer electrophoresis
cell. The proteins were stained either with alkaline
silver or with Coomassie blue. For immunostaining
of the Pgp, the first and second antibodies were 1:250
diluted monoclonal anti-MDR antibody from mouse
 .C219, Signet, Dedham, MA and 1:5000 diluted
anti-mouse Ig, peroxidase-linked whole antibody from
 .sheep Amersham , respectively. For yeast plasma
membrane Hq-ATPase detection, the first antibody
was 1:100 000 diluted polyclonal antiserum from rab-
w xbit 30 , and the second antibody was 1:5000 diluted
anti-rabbit Ig, peroxidase-linked whole antibody from
 .donkey Amersham . The peroxidase-labeled blots
were developed by the enhanced chemiluminescence
method, using the Amersham Corp. ECL kit.
2.9. Glycosidase treatment
Samples of 3 mg of the purified Pgp in 0.1%
 .  .wrv DDM and 10 mg of fetuin Sigma were
 .mixed and denatured by incubation with 0.5% wrv
 .SDS, 1% vrv b-mercaptoethanol for 10 min at
 .508C. The samples were adjusted to 0.5% vrv
 .Nonidet P-40 Boehringer Mannheim , and 0.1 unit
 .  .of N-glycosidase F Sigma or water to control tube
was added. The samples were incubated at 378C over
night and then analyzed by SDS–PAGE in 7.5%
acrylamide gels that were either stained with
Coomassie blue or subjected to immunoblotting for
the Pgp.
2.10. Estimation of protein
Protein concentrations were determined by the
Lowry procedure, as modified by Bensadoun and
w xWeinstein 31 using bovine serum albumin as stan-
dard.
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2.11. Other materials
The sources of most of the materials have been
w xdescribed previously 17,21,22 . Yeast strain BJ1991
was from the Yeast Genetics Stock Center, Univer-
sity of California, Berkeley, CA. Human Pgp bac-
ulovirus infected Sf9 cell membranes were prepared
by Mr. Michael Hoben in this laboratory, as de-
w x 2qscribed previously 17 . Ni -NTA Superflow resin
was from Qiagen.
3. Results
Systems for the expression of the N. crassa plasma
membrane Hq-ATPase and the CFTR in yeast have
w xbeen previously established in this laboratory 21,22 .
On the basis of these experiments, two yeast expres-
sion vectors containing the wild-type human mdr1
cDNA were constructed, as described in Section 2. In
these vectors Pgp expression is under the control of
the constitutive promoter of the yeast plasma mem-
brane Hq-ATPase. Fig. 1 shows the map of plasmid
pQMMDR4, which was used throughout this study.
In order to facilitate Pgp purification by Ni2q affinity
chromatography, which has proved very useful for
w xthe purification of membrane proteins 20,28,32–34 ,
a histidine tag coding for 10 tandem histidines was
introduced at the C-terminal end of the Pgp cDNA in
pQMMDR4. Plasmid pQMMDR3 is similar without
a histidine tag. In addition, all of the three in-frame
ATTs upstream from the ATG start codon in the
expression vectors were deleted in order to prevent
N-terminal peptide extension caused by translation
w xinitiation at an upstream in-frame ATT 22 . When
the expression vectors were transformed into yeast
strain EGY48, which was previously used for expres-
w xsion of the CFTR 22 , only a low level of expression
was detected, due to substantial proteolytic degrada-
 .tion of the expressed Pgp data not shown . We
therefore switched to the yeast strain BJ1991, which
is proteinase-deficient and has been successfully used
for the expression of the human AE1 anion ex-
w xchanger with a high yield 28 . Individual colonies
were grown and isolated membranes analyzed for
Pgp expression by SDS–PAGE followed by silver
staining and immunoblotting. Fig. 2A shows an
SDS–PAGE analysis of membranes isolated from
 .Fig. 2. Expression of the human Pgp in yeast membranes. A
Silver-stained yeast membrane proteins in a 7.5% acrylamide
SDS–PAGE minigel. Lane 1, membranes of control strain
 . RS421-Not 3 mg . Lane 2, membranes of strain QMMDR4 3
.  .mg . The arrow indicates the 130 kDa Pgp band. B Immunoblot
analyses of the Pgp expressed in yeast strain BJ1991. Membranes
of strains QMMDR3 and QMMDR4 were prepared as described
in Section 2 and subjected to SDS–PAGE in a 7.5% acrylamide
minigel. Western blotting of the SDS–PAGE gel of the total
membranes was then carried out as described in Section 2. The
identities of the strains used are indicated above the lanes. Lanes
1 and 3: 20 mg of yeast membranes; lanes 2 and 4: 40 mg of
yeast membranes; lanes 5 and 6: 5 and 10 mg of Pgp bac-
ulovirus-infected Sf9 insect cell membranes, respectively.
control strain RS421-Not and strain QMMDR4
stained with silver. The band of the Pgp in QM-
 .MDR4 membranes Fig. 2A, lane 2 is easily seen in
the position indicated by the arrow. No corresponding
band at the position of the Pgp is observed in the
 .control membranes Fig. 2A, lane 1 . Since the Pgp
band in such analyses is closely flanked by other
proteins, its expression level could not be accurately
quantified by direct densitometry. We therefore quan-
tified the Pgp yield in a different way. The amount of
the Pgp produced in Sf9 insect cell membranes is
larger than that in the yeast membranes and can be
estimated by densitometry of silver-stained gels. By
this method, the Pgp produced in Sf9 cells represents
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Fig. 3. Influence of expression of the Pgp on yeast cell growth.
Time-dependent growth of the strain BJ1991 transformed with
 .the control plasmid pRS421-Not B and the Pgp expression
 .plasmid pQMMDR4 v were estimated by measuring the opti-
 .cal density A in liquid cultures prepared as described in600nm
Section 2.
about 3% of the total protein in the light membrane
w xfraction 17 . Fig. 2B shows an immunoblot of mem-
branes isolated from yeast strains QMMDR3 and
QMMDR4, and Pgp-expressing Sf9 insect cells. The
amount of the Pgp in the membranes of strain QM-
MDR4 is about 15% of that in Sf9 cell membranes as
determined by densitometry of the immunoblots.
Thus, the Pgp is produced in strain QMMDR4 in
amounts approximately 0.4% of the total yeast mem-
brane proteins, a level similar to that of the CFTR
w xproduced in this yeast expression system 22 . Fig.
2B also shows that introduction of a histidine tag to
the C-terminus of the Pgp does not interfere with its
expression level, because there is no noticeable dif-
ference in Pgp expression between strains QMMDR3
and QMMDR4. Since strain QMMDR4 produces a
wild-type human Pgp with a histidine tag at its
C-terminus for protein purification, all subsequent
experiments were carried out primarily with the Pgp
produced in strain QMMDR4.
Fig. 3 shows the growth rate of the yeast cells
transformed with a control plasmid or plasmid pQM-
MDR4. The growth rate of cells expressing the Pgp
 .was much slower doubling time longer than 7 h
than cells transformed with control vector pRS421-
 .Not doubling time around 3 h . These results indi-
cate that expression of the Pgp can interfere with
yeast growth. Similar results were also obtained for
w xthe human AE1 anion exchanger 28 and the CFTR
 .P. Huang and Q. Mao, unpubl. observation , sug-
gesting that this is probably a general effect of forced
expression of foreign proteins.
To determine the subcellular distribution of the
human Pgp expressed in this yeast system, crude
membranes from strain QMMDR4 were fractionated
by discontinuous sucrose gradient centrifugation and
membrane-containing fractions were analyzed by im-
munoblotting for the Pgp and the yeast plasma mem-
brane Hq-ATPase. The results of this experiment are
shown in Fig. 4. The expressed Pgp and the yeast
plasma membrane Hq-ATPase comigrated, and were
enriched near the bottom of the gradient, indicating
that the majority of the Pgp expressed in this yeast
system is directed to the plasma membrane.
The next question of obvious interest regards the
functionality of the Pgp expressed in yeast. To ad-
dress this question we first determined the phenotypic
consequence of Pgp expression. Valinomycin, a pep-
tide antibiotic that markedly stimulates the Pgp–
w xATPase activity 35 and is thus a presumed Pgp
substrate, has been shown to be toxic to yeast cells
w x14,36 . We therefore carried out growth tests to
determine whether or not the yeast cells expressing
the Pgp display a drug-resistant phenotype. Fig. 5A
shows the results of one such experiment. In the
absence of valinomycin the control strain RS421-Not
grows somewhat better than the Pgp-expressing strain
QMMDR4, consistent with the results of Fig. 3 Fig.
Fig. 4. Subcellular distribution of the expressed Pgp. Shown are
 .immunoblots of the Pgp upper panel and the yeast plasma
q  .membrane H -ATPase lower panel on the same blot. Fraction
numbers from the top to the bottom of the gradient are shown
above each lane. Only the fractions indicated were analyzed.
SDS–PAGE was carried out in a 7.5% acrylamide minigel. See
Section 2 for details.
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Fig. 5. Expression of the Pgp confers valinomycin-resistance to
 .yeast cells. A BJ1991 cells carrying plasmids pQMMDR4 and
 .pRS421-Not were spotted on agar plates without lane 1 or with
 .lane 2 150 mM valinomycin, as described in Section 2. Cell
growth was recorded after 48 h at 308C. The identities of strains
 .  .QMMDR4 and RS421-Not are indicated. B and C Effect of
 .valinomycin on the growth of the control strain RS421-Not B
 .and Pgp-expressing strain QMMDR4 C . Cells were grown in
synthetic media in the presence of different concentrations of
valinomycin at 308C as described in Section 2. Valinomycin
 .  .  .concentrations are 0 B , 20 mgrml v , 55 mgrml ’ , 110
 .  .  .mgrml e , 130 mgrml I and 165 mgrml ‘ . Shown are
means of two independent experiments.
.5A, lane 1 . However, strain RS421-Not grows sig-
nificantly slower than strain QMMDR4 in the pres-
 .ence of valinomycin Fig. 5A, lane 2 . To obtain a
more quantitative estimate of the valinomycin resis-
tance conferred by the expressed Pgp, growth experi-
ments in liquid medium were carried out. Fig. 5B,C
summarize the results of these experiments. Signifi-
cant inhibition of growth of the control strain is seen
at 55 mgrml of valinomycin, and increasing inhibi-
tion occurs as the valinomycin concentration is in-
creased. In contrast, growth of the Pgp-expressing
strain is unaffected between 0 and 165 mgrml of
valinomycin. Interestingly, the valinomycin effects
on the growth of the control strain are eventually
overcome in the liquid medium experiments, presum-
ably due to the development of some form of yeast
w xdrug resistance 37 . Thus, yeast cells expressing the
Pgp acquire a dramatically increased resistance to
valinomycin, suggesting that at least some of the Pgp
expressed in yeast is functional.
To assess the functionality of the expressed Pgp
further it was necessary to solubilize and purify it,
because its activity in the crude yeast membrane
fraction is masked by a variety of other endogenous
ATPase activities. This was greatly aided by the
presence of the deca-histidine tag at the C-terminus
of the expressed Pgp. We first determined suitable
conditions for solubilizing the Pgp from the yeast
membranes. Fig. 6 summarizes the most important
observations from these experiments. In the absence
of NaCl, only 10–20% of the Pgp is solubilized from
the yeast membranes by 1% DDM or 1% LPC,
respectively, as judged from densitometric analyses
of these immunoblots. However, when 400 mM NaCl
is added to the solubilization buffer, 70–80% of the
Pgp is solubilized by DDM and 80–90% by LPC.
Although not shown, octyl-b-glucoside solubilized
about 40–50% of the Pgp, but the addition of NaCl
had little effect. On the basis of these experiments,
initial solubilization of the Pgp is carried out with 1%
 .wrv LPC in the presence of 400 mM NaCl.
In initial purification trials the LPC-solubilized
Pgp was applied onto a nickel spin column but most
Fig. 6. Solubilization of the Pgp from yeast membranes. QM-
 .MDR4 membranes 1 mg of protein were resuspended in 0.5 ml
of solubilization buffer 25 mM Tris, 1 mM PMSF, 2 mgrml
chymostatin, leupeptin, pepstatin A and aprotinin, 1 mM b-mer-
 . .captoethanol, and 20% wrv glycerol, pH 8.0 with HCl con-
 .  .taining 1% wrv LPC or 1% wrv DDM with or without 400
mM NaCl as indicated. Samples were incubated at 48C with
gentle stirring for 20 min and centrifuged for 45 min at 100000
 .= g 48C . The supernatants were collected, and the pellets from
each sample were thoroughly resuspended in 0.5 ml of solubiliza-
 .tion buffer lacking detergent. The same volume 20 ml of
 .  .supernatants S and pellets P was disaggregated and subjected
to SDS–PAGE in a 7.5% acrylamide minigel, and processed for
immunoblotting of the Pgp. See Section 2 for additional details.
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Fig. 7. Purification of the yeast-expressed Pgp by Ni2q affinity
 .chromatography. QMMDR4 membranes 20 mg of protein were
solubilized with LPC, the supernatant collected, and the solubi-
lized Pgp was purified by Ni2q affinity chromatography as
described in Section 2. Lane 1, molecular weight markers; lane 2,
 .starting material LPC-solubilized extract ; lane 3, flow-through;
lane 4, pool of wash with 30 mM imidazole buffer; lane 5, pool
of wash with 60 mM imidazole buffer; lanes 6–19, fractions
eluted with 250 mM imidazole buffer. Aliquots of the samples
 .25 ml for each lane were subjected to SDS–PAGE in 7.5%
acrylamide, 15=15=0.075 cm gels that were then either trans-
ferred to nitrocellulose membrane for immunoblotting of the Pgp
 .  .A or stained with alkaline silver B . The molecular masses of
the protein standards are indicated to the left of the gel in panel
B.
of the Pgp failed to bind to the column. However, it
has been observed that incubation of solubilized
membrane proteins with the Ni2q-NTA resin for
about 1 h at 48C can significantly improve protein
w xbinding 33 and, when the LPC-solubilized Pgp was
applied to the Ni2q-NTA resin in this way, binding
was greatly improved. Fig. 7 shows the results of a
typical Pgp purification experiment. More than 90%
of the solubilized Pgp is bound to the nickel resin, as
judged by densitometry of the immunoblots of the
 .starting material Fig. 7A, lane 2 and the flow-
 .through after protein binding Fig. 7A, lane 3 . After
Table 1
Protein recovery during the LPC solubilization and the Ni2q
affinity chromatography of the Pgp
Steps Protein Yield of Pgp
 .  .mg %
Crude membrane 20 100
LPC-solubilized extract 13 81
Flow-through 11 –
Purified Pgp 0.05 63
 .Crude membranes 20 mg of protein were prepared as described
in Section 2. The yield of Pgp at each step is calculated relative
 .to the overall Pgp present in the plasma membranes 100% .
elution with 250 mM imidazole, the Pgp is concen-
 .trated in just a few fractions Fig. 7A, lanes 9–12 .
Panel B of Fig. 7 shows a silver stained SDS–PAGE
gel analyses of the same fractions. The Pgp emerges
from the Ni2q-NTA column in nearly pure form.
Table 1 indicates the yields of protein present in the
various fractions of the experiment of Fig. 7. About
50 mg of purified Pgp protein is obtained from 20 mg
of crude yeast membranes. From quantitative im-
munoblots, we estimate that 20 mg of such mem-
branes contain about 80 mg of the Pgp. Thus, the
recovery of the Pgp solubilization and purification
procedures is greater than 60%. In addition to its
remarkable ease and effectiveness, the Ni2q-NTA
purification procedure provides an additional advan-
tage in that it readily facilitates detergent exchange.
Thus, since LPC tends to precipitate on standing at
Fig. 8. Verapamil-stimulated ATPase activity of the purified Pgp.
ATPase activity of the purified Pgp was determined in the
presence of E. coli lipids and several concentrations of vera-
pamil, as described in Section 2. Shown are means and standard
deviations of five independent experiments.
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48C, we routinely exchanged it for DDM during the
Ni2q affinity chromatography step.
The availability of highly purified Pgp allows a
direct assessment of its functionality. A reliable index
of the functionality of the Pgp is its verapamil-stimu-
w xlated ATPase activity 17 . Fig. 8 shows the vera-
pamil concentration dependence of the ATPase activ-
ity of the purified wild-type Pgp. In the absence of
verapamil, the purified Pgp has an ATPase activity of
about 0.9 mmolrmin per mg of Pgp. In the light of
recent data supporting the notion that the Pgp is a
w xlipid translocase of broad specificity 38 , the activity
we detect in the absence of verapamil is most likely
due to the presence of other Pgp substrates, such as
the E. coli lipids added to the assay or the detergents
used in the purification procedure. With increasing
concentrations of verapamil, the ATPase activity in-
creases 2.8-fold to 2.5 mmolrmin per mg of Pgp,
which is comparable to the highest activities reported
w xfrom other laboratories 11,12,20,39,40 .
The immunoblot analyses shown in Fig. 2B shows
that there is no noticeable mobility difference be-
tween the Pgp expressed in yeast and that produced
in Sf9 insect cells, suggesting that the Pgp produced
in yeast is not substantially glycosylated. To assess
Fig. 9. Effect of N-glycosidase F treatment on the purified Pgp
produced in yeast. A mixture of the purified Pgp and glycosy-
lated control protein, fetuin, were treated with or without N-gly-
cosidase F and analyzed by SDS–PAGE, as described in Section
 .  .2. A Coomassie blue-stained SDS–PAGE gel. B Immunos-
taining for the Pgp. Electrophoresis was carried out in a 7.5%
acrylamide, 15=15=0.075 cm gel. Positions of the Pgp and
fetuin before treatment are indicated by arrows. Lane 1, sample
treated with N-glycosidase F; lane 2, control without glycosidase
treatment.
further whether or not the Pgp expressed in yeast is
glycosylated, the effect of N-glycosidase F treatment
on the purified Pgp was determined. In this experi-
ment, the Pgp purified as described above and a
glycosylated control protein, fetuin, were mixed and
together treated with N-glycosidase F as previously
w xdescribed 28 , and the electrophoretic mobility of the
Pgp with and without N-glycosidase F treatment was
assessed by SDS–PAGE. Fig. 9A shows such a gel
stained with Coomassie blue and Fig. 9B shows the
results of an immunoblot. Whereas fetuin exhibited a
marked mobility increase upon the N-glycosidase F
treatment, the mobility of the Pgp was unaltered,
suggesting that the Pgp expressed in yeast is not
glycosylated. This conclusion is in agreement with
w xthe observations of Kuchler and Thorner 14 . Fi-
nally, the purified Pgp has an electrophoretic mobility
corresponding to a molecular mass of about 130 kDa,
which is in good agreement with the molecular mass
of the unglycosylated human Pgp predicted from the
gene sequence.
4. Discussion
The results we have obtained in this study demon-
strate that the human Pgp can be functionally ex-
pressed in S. cere˝isiae in significant yields. It is
estimated that the recombinant Pgp is produced in
amounts approximately 0.4% of the total yeast mem-
brane protein. Several factors contributed to this sub-
stantial level of Pgp expression. First, the expression
system used allows for a high gene copy number, due
to a multicopy plasmid and a high transcriptional
activity owing to the strong constitutive yeast plasma
q w xmembrane H -ATPase promoter 23 . Although not
studied here, another factor possibly contributing to
this yield of the Pgp is the optimized arrangement of
the bases in the promoter region just preceding the
ATG start codon of the Pgp. As we have previously
shown, deletion of in-frame ATTs upstream from the
ATG start codon dramatically increases the level of
w xexpression of the CFTR in this system 22 . For this
reason, plasmids pQMMDR3 and pQMMDR4 were
constructed without these upstream ATTs to mimic
the CFTR expression plasmid, pHCFTRW, described
w xby Huang et al. 22 . The choice of the host yeast
strain used for these studies was also an important
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factor for obtaining significant levels of expression of
the Pgp. Initially, the Pgp expression plasmid was
transformed into the yeast strain EGY48, which was
w xpreviously used for the expression of the CFTR 22 .
However, the expression level of the Pgp in strain
EGY48 was low and variable, due to proteolytic
degradation of the expressed Pgp by endogenous
yeast proteinases. The use of the yeast strain BJ1991,
w xwhich is proteinase-deficient 41 , led to a substantial
decrease in Pgp degradation and a concomitant in-
crease in intact Pgp production.
Pgp has been studied exhaustively for many years
in living organisms and at the cellular and subcellular
levels. More recently, it has become possible to study
certain enzymatic features of this important molecule
w xat the biochemical level 17,10,9–12,15,20,42,43 .
However, at present, little is known regarding the
structure of Pgp and the molecular mechanism by
which it confers multidrug resistance to cells in which
it is over-expressed. Progress in this regard will
require the development of procedures for isolating
Pgp in large quantities and the determination of its
structure at low resolution by biochemical means and,
ultimately, at higher resolution by electron crystallog-
w xraphy of 2-dimensional crystals 44 or X-ray crystal-
w xlography of 3-dimensional crystals 45–47 . A variety
of systems are available for Pgp production, includ-
w xing the drug-resistant cultured cell systems 9–12
and heterologous expression systems in Sf9 insect
w x w x w xcell 16,17 , E. coli 18,19 , yeast 13–15,48 , and
w xtransiently transfected HEK293 cells 20 . However,
only a few of these are capable of producing the high
levels of the Pgp needed for extensive biochemical
and biophysical studies. Of these, the system using
drug-resistant cultured cells may be highly useful, but
a major concern with these systems is the extensive
level of Pgp glycosylation, which may preclude crys-
tallization. The expensive and tedious procedures for
maintaining the cultured cells are another significant
drawback with these systems. Another Pgp produc-
tion system currently available is the Sf9 cultured
insect cell system, which offers yields of the Pgp up
to about 3% of the insect cell light membrane frac-
w xtion 17 . In addition to this high yield, this system
offers an under-glycosylated Pgp, which may be eas-
ier to crystallize. However, a major drawback of this
system is the expense and labor of the insect cell
growth and maintenance, which makes obtaining large
amounts of starting material for Pgp purification dif-
ficult, at best.
Heterologous Pgp expression systems using mi-
croorganisms can potentially obviate the above men-
tioned problems with cultured animal and insect cell
expression systems. Several such systems have been
w xreported 13–15,18,19,48 but the expression levels
are difficult to estimate from the data provided. The
Pgp expression system described here produces Pgp
at levels somewhat less than that of the cultured
animal and insect cell systems, on a milligram of
membrane protein basis. However, the low cost and
ease with which massive quantities of yeast cells can
be grown more than compensate for the lower yield
compared to the other systems. The Pgp produced in
yeast is also apparently unglycosylated, and site-di-
rected mutants can readily be generated. Moreover,
with the deca-histidine tag attached, the recombinant
Pgp is extremely easy to purify. Finally, the Ni2q
chelate chromatography step offers a easy means for
detergent exchange, which may be indispensable for
Pgp crystallization experiments.
In summary, we have expressed the human Pgp
with substantial yields in a yeast system used previ-
ously to produce recombinant transport ATPases and
the CFTR. We have also purified the Pgp from the
yeast membranes to near homogeneity in functional
form using Ni2q affinity chromatography. This yeast
expression and purification system should provide an
excellent source of material for biochemical and bio-
physical studies aimed at elucidating the molecular
structure and mechanism of drug transport catalyzed
by the Pgp. The results obtained may be also of value
for the heterologous expression and purification of
other integral membrane proteins, including other
medically important mammalian ABC transporters.
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